SANTA CLARA & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq: AFFX) and Iconix Biosciences today announced the launch of the ToxFX™ Analysis Suite, a toxicogenomics solution that improves researchers’ understanding of safety issues associated with new drug candidates, compounds or environmental toxicants. ToxFX, which combines Iconix’ revolutionary automated analysis with Affymetrix’ GeneChip® arrays, helps scientists prioritize drug candidates and make preclinical development decisions faster than ever before.
